(Q46682601)

24 December 2017

title

The Early Prostate Cancer program: bicalutamide in nonmetastatic prostate cancer (English)

1 reference

24 December 2017

1 reference

1 reference

Peter Iversen

1

1 reference

24 December 2017

Martin Andreas Roder

series ordinal

2

1 reference

24 December 2017

publication date

1 March 2008

1 reference

24 December 2017

Expert Review of Anticancer Therapy

published in

1 reference

24 December 2017

volume

8

1 reference

24 December 2017

issue

3

1 reference

24 December 2017

page(s)

361-369

1 reference

24 December 2017

Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31.

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.361

Four prognostic groups predict long-term survival from prostate cancer following radiotherapy alone on Radiation Therapy Oncology Group clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.361

Radical prostatectomy versus watchful waiting in early prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.361

Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.361

Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.361

BICALUTAMIDE MONOTHERAPY COMPARED WITH CASTRATION IN PATIENTS WITH NONMETASTATIC LOCALLY ADVANCED PROSTATE CANCER: 6.3 YEARS OF FOLLOWUP

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.361

Testosterone and coronary heart disease: is there a link?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.361

Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.361

Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.361

Associations between serum testosterone fall and cognitive function in prostate cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.361

Does neoadjuvant hormone therapy for early prostate cancer affect cognition? Results from a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.361

Long-term effects of androgen deprivation therapy in prostate cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.361

Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.361

Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.361

Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.361

The bicalutamide Early Prostate Cancer Program. Demography

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.361

Bicalutamide as Immediate Therapy Either Alone or as Adjuvant to Standard Care of Patients with Localized or Locally Advanced Prostate Cancer: First Analysis of the Early Prostate Cancer Program

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.361

Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.361

Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.361

Bicalutamide 150 mg in addition to standard care for patients with early non-metastatic prostate cancer: updated results from the Scandinavian Prostate Cancer Period Group-6 Study after a median follow-up period of 7.1 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.361

Complications of advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.361

Prophylactic breast irradiation with a single dose of electron beam radiotherapy (10 Gy) significantly reduces the incidence of bicalutamide-induced gynecomastia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.361

Efficacy and tolerability of radiotherapy as treatment for bicalutamide-induced gynaecomastia and breast pain in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.361

Prevention and management of bicalutamide-induced gynecomastia and breast pain: randomized endocrinologic and clinical studies with tamoxifen and anastrozole

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.361

Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.361

Tamoxifen as prophylaxis for prevention of gynaecomastia and breast pain associated with bicalutamide 150 mg monotherapy in patients with prostate cancer: a randomised, placebo-controlled, dose-response study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.361

Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.361

Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.361

A randomised comparison of bicalutamide ('Casodex') 150 mg versus placebo as immediate therapy either alone or as adjuvant to standard care for early non-metastatic prostate cancer. First report from the Scandinavian Prostatic Cancer Group Study No.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.361

Tolerability of Antiandrogens in the Treatment of Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.361

21 January 2018

Identifiers

DOI

10.1586/14737140.8.3.361

1 reference

24 December 2017

1 reference

24 December 2017